10-Q: Healthy Extracts Inc. Reports Q3 2024 Results, Revenue Up 29% Year-Over-Year

Healthy Extracts Inc. saw a 29% increase in revenue year-over-year for the nine months ended September 30, 2024, while also reporting a net loss.

Summary

• Healthy Extracts Inc. reported a revenue of $2,342,091 for the nine months ended September 30, 2024, a 29% increase compared to $1,816,968 for the same period in 2023.
• The company's cost of revenue increased to $845,185 for the nine months ended September 30, 2024, up from $760,825 in the prior year.
• Gross profit for the nine months ended September 30, 2024, was $1,496,906, a 42% increase from $1,056,143 in 2023.
• Operating expenses decreased significantly to $1,485,945 for the nine months ended September 30, 2024, compared to $2,977,998 in 2023.
• The company reported a net loss of $393,742 for the nine months ended September 30, 2024, compared to a net loss of $2,094,316 for the same period in 2023.
• The company's cash balance increased to $100,402 as of September 30, 2024, from $19,441 at the end of 2023.
• The company had positive operating cash flow of $240,090 for the nine months ended September 30, 2024, compared to negative cash flow of $(471,373) for the same period in 2023.
• The company's accumulated deficit increased to $18,793,415 as of September 30, 2024.

Sentiment

Score: 6

Explanation: The document shows significant improvements in revenue, cost management, and cash flow, but the company still faces challenges with profitability and going concern issues. The sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in revenue, indicating strong sales growth.
• Gross profit increased substantially, showing improved profitability on sales.
• Operating expenses were significantly reduced, demonstrating better cost management.
• The net loss decreased substantially, indicating improved financial performance.
• The company's cash position improved, providing more financial flexibility.
• The company generated positive operating cash flow, indicating improved operational efficiency.
• Cost of revenue as a percentage of revenues decreased, indicating improved efficiency in production and sales.

Negatives

• The company still reported a net loss for the nine months ended September 30, 2024, indicating ongoing financial challenges.
• The company's accumulated deficit increased, reflecting the history of losses.
• The company has a history of losses and has substantial doubt about its ability to continue as a going concern.
• The company relies on debt and equity financing to sustain operations.

Risks

• The company has a history of losses and has substantial doubt about its ability to continue as a going concern.
• The company relies on debt and equity financing to sustain operations, which may not always be available.
• The company's products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy.
• The company's future results and shareholder values may differ materially from those expressed in forward-looking statements due to risks, uncertainties, and assumptions.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level due to material weaknesses identified in the Annual Report on Internal Control Over Financial Reporting.

Future Outlook

The company expects strong growth to increase as its direct consumer sales and marketing efforts continue to perform and anticipates that cash needs will be satisfied through increased revenues and the issuance of debt or the sale of securities until such time as cash flows from operations will satisfy cash flow needs.

Management Comments

• Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entitys ability to continue as a going concern.
• Management believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary.
• Management has provided for any risks in the current inventory allowance booked.

Industry Context

The company operates in the nutraceuticals market, which is a high-growth sector. The company's focus on heart, brain, and immune health aligns with current consumer trends and demands.

Comparison to Industry Standards

• The company's revenue growth of 29% year-over-year is a positive sign, but it is important to compare this to the average growth rate of other companies in the nutraceuticals industry.
• The company's reduction in operating expenses by 50% year-over-year is a significant improvement, but it is important to assess whether this is sustainable and if it is in line with industry benchmarks.
• The company's net loss of $393,742 for the nine months ended September 30, 2024, is an improvement compared to the net loss of $2,094,316 for the same period in 2023, but it is important to compare this to the profitability of other companies in the industry.
• The company's cash balance of $100,402 as of September 30, 2024, is a positive sign, but it is important to assess whether this is sufficient to cover the company's operating expenses and capital requirements.
• The company's positive operating cash flow of $240,090 for the nine months ended September 30, 2024, is a positive sign, but it is important to assess whether this is sustainable and if it is in line with industry benchmarks.
• The company's reliance on debt and equity financing is a common practice for early-stage companies, but it is important to assess the company's ability to secure financing on favorable terms and to manage its debt obligations.
• The company's products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy, which is a risk factor that is important to consider when comparing the company to other companies in the industry.

Related Party Transactions

• The company had expenses totaling $0 and $0 respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying consolidated statement of operations.
• The company has related party notes payable outstanding.

Stakeholder Impact

• Shareholders may be encouraged by the improved financial performance, but should be aware of the going concern risk.
• Employees may be impacted by the company's financial situation and potential need for cost-cutting measures.
• Customers may benefit from the company's continued growth and product development.
• Suppliers may be impacted by the company's financial situation and potential need for cost-cutting measures.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on increasing direct consumer sales and marketing efforts.
• The company will continue to seek funding through debt and equity financing.
• The company will continue to monitor and manage its cash flow and operating expenses.

Key Dates

Keywords

nutraceuticals, revenue, financial results, net loss, operating expenses, gross profit, cash flow, debt, equity, going concern, derivative liability, stock warrants, convertible debt